<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35675776</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>10</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>07</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Drug screen in iPSC-Neurons identifies nucleoside analogs as inhibitors of (G<sub>4</sub>C<sub>2</sub>)<sub>n</sub> expression in C9orf72 ALS/FTD.</ArticleTitle><Pagination><StartPage>110913</StartPage><MedlinePgn>110913</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2022.110913</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(22)00690-8</ELocationID><Abstract><AbstractText>An intronic (G<sub>4</sub>C<sub>2</sub>)<sub>n</sub> expansion in C9orf72 causes amyotrophic lateral sclerosis and frontotemporal dementia primarily through gain-of-function mechanisms: the accumulation of sense and antisense repeat RNA foci and dipeptide repeat (DPR) proteins (poly-GA/GP/GR/PA/PR) translated from repeat RNA. To therapeutically block this pathway, we screen a library of 1,430 approved drugs and known bioactive compounds in patient-derived induced pluripotent stem cell-derived neurons (iPSC-Neurons) for inhibitors of DPR expression. The clinically used guanosine/cytidine analogs decitabine, entecavir, and nelarabine reduce poly-GA/GP expression, with decitabine being the most potent. Hit compounds nearly abolish sense and antisense RNA foci and reduce expression of the repeat-containing nascent C9orf72 RNA transcript and its mature mRNA with minimal effects on global gene expression, suggesting that they specifically act on repeat transcription. Importantly, decitabine treatment reduces (G<sub>4</sub>C<sub>2</sub>)<sub>n</sub> foci and DPRs in C9orf72 BAC transgenic mice. Our findings suggest that nucleoside analogs are a promising compound class for therapeutic development in C9orf72 repeat-expansion-associated disorders.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Czuppa</LastName><ForeName>Mareike</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dhingra</LastName><ForeName>Ashutosh</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, Germany. Electronic address: ashutosh.dhingra@dzne.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Qihui</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schludi</LastName><ForeName>Carina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xf6;nig</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scharf</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farny</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dalmia</LastName><ForeName>Anupriya</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>T&#xe4;ger</LastName><ForeName>Joachim</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castillo-Lizardo</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katona</LastName><ForeName>Eszter</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mori</LastName><ForeName>Kohji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Psychiatry, Graduate School of Medicine, Osaka University, Suita, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aumer</LastName><ForeName>Tina</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Ludwig-Maximilians-University Munich, Faculty of Chemistry and Pharmacy, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schelter</LastName><ForeName>Florian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Ludwig-Maximilians-University Munich, Faculty of Chemistry and Pharmacy, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Ludwig-Maximilians-University Munich, Faculty of Chemistry and Pharmacy, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carell</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Ludwig-Maximilians-University Munich, Faculty of Chemistry and Pharmacy, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalliokoski</LastName><ForeName>Tuomo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Orion Corporation Orion Pharma, Medicine Design, Espoo, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Messinger</LastName><ForeName>Josef</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Orion Corporation Orion Pharma, Medicine Design, Espoo, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rizzu</LastName><ForeName>Patrizia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heutink</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, Germany; Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edbauer</LastName><ForeName>Dieter</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany; Ludwig-Maximilians-University Munich, Graduate School of Systemic Neurosciences (GSN), Munich, Germany. Electronic address: dieter.edbauer@dzne.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004151">Dipeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009705">Nucleosides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016372">RNA, Antisense</NameOfSubstance></Chemical><Chemical><RegistryNumber>776B62CQ27</RegistryNumber><NameOfSubstance UI="D000077209">Decitabine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077209" MajorTopicYN="N">Decitabine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004151" MajorTopicYN="N">Dipeptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="Y">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009705" MajorTopicYN="N">Nucleosides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016372" MajorTopicYN="N">RNA, Antisense</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">C9orf72</Keyword><Keyword MajorTopicYN="N">CP: Neuroscience</Keyword><Keyword MajorTopicYN="N">DPR</Keyword><Keyword MajorTopicYN="N">FTD</Keyword><Keyword MajorTopicYN="N">RAN translation</Keyword><Keyword MajorTopicYN="N">RNA foci</Keyword><Keyword MajorTopicYN="N">iPSC neurons</Keyword><Keyword MajorTopicYN="N">nucleoside analogs</Keyword><Keyword MajorTopicYN="N">repeat expansion</Keyword><Keyword MajorTopicYN="N">screening</Keyword></KeywordList><CoiStatement>Declaration of interests T.K. and J.M. are employees of Orion Pharma. The other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>8</Day><Hour>18</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35675776</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2022.110913</ArticleId><ArticleId IdType="pii">S2211-1247(22)00690-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>